中国人群中 GSTP1、ERCC1 和 ERCC2 基因多态性、表达与奥沙利铂辅助化疗在结直肠癌中的临床结局
GSTP1, ERCC1 and ERCC2 polymorphisms, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in colorectal cancer in Chinese population.
作者信息
Li Hui-Yan, Ge Xin, Huang Guang-Ming, Li Kai-Yu, Zhao Jing-Quan, Yu Xi-Miao, Bi Wen-Si, Wang Yu-Lin
机构信息
Department of Radiology, the Third Affiliated Hospital of Harbin Medical University, Harbin, China.
出版信息
Asian Pac J Cancer Prev. 2012;13(7):3465-9. doi: 10.7314/apjcp.2012.13.7.3465.
AIM
Platinum agents have shown to be effective in the treatment of colorectal cancer. We assessed whether single nucleotide polymorphisms (SNPs) in GSTP1, ERCC1 Asn118Asn and ERCC2 Lys751Gln might predict the overall survival in patients receiving oxaliplatin-based chemotherapy in a Chinese population.
METHODS
SNPs of GSTP1, ERCC1 Asn118Asn and ERCC2 Lys751Gln in 335 colorectal cancer patients were assessed using TaqMan nuclease assays.
RESULTS
At the time of final analysis on Nov. 2011, the median follow-up period was 37.7 months (range from 1 to 60 months). A total of 229 patients died during follow-up. Our study showed GSTP1 Val/Val (HR=0.44, 95% CI=0.18-0.98), ERCC1 C/C (HR=0.20, 95% CI=0.10-0.79) and ERCC2 G/G (HR=0.48, 95% CI=0.19-0.97) to be significantly associated with better survival of colorectal cancer. GSTP1 Val/Val, ERCC1 C/C and ERCC2 G/G were also related to longer survival among patients with colon cancer, with HRs (95% CIs) of 0.41 (0.16-0.91), 0.16 (0.09-0.74) and 0.34 (0.16-0.91), respectively.
CONCLUSION
GSTP1, GSTP1, ERCC1 Asn118Asn and ERCC2 Lys751Gln genotyping might facilitate tailored oxaliplatin-based chemotherapy for colorectal cancer patients.
目的
铂类药物已显示出对结直肠癌治疗有效。我们评估了谷胱甘肽S-转移酶P1（GSTP1）、切除修复交叉互补基因1（ERCC1）Asn118Asn单核苷酸多态性以及ERCC2 Lys751Gln是否能预测中国人群中接受奥沙利铂化疗患者的总生存期。
方法
采用TaqMan核酸酶分析方法评估335例结直肠癌患者的GSTP1、ERCC1 Asn118Asn和ERCC2 Lys751Gln单核苷酸多态性。
结果
在2011年11月进行最终分析时，中位随访期为37.7个月（范围为1至60个月）。共有229例患者在随访期间死亡。我们的研究表明，GSTP1 Val/Val（风险比[HR]=0.44，95%置信区间[CI]=0.18 - 0.98）、ERCC1 C/C（HR=0.20，95% CI=0.10 - 0.79）和ERCC2 G/G（HR=0.48，95% CI=0.19 - 0.97）与结直肠癌患者更好的生存率显著相关。GSTP1 Val/Val、ERCC1 C/C和ERCC2 G/G在结肠癌患者中也与更长的生存期相关，HR（95% CI）分别为0.41（0.16 - 0.91）、0.16（0.09 - 0.74）和0.34（0.16 - 0.91）。
结论
GSTP1、ERCC1 Asn118Asn和ERCC2 Lys751Gln基因分型可能有助于为结直肠癌患者量身定制基于奥沙利铂的化疗方案。
Zotero 插件